Home>Topics>Stocks>Amicus Therapeutics

Amicus Therapeutics FOLD

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Amicus Therapeutics' ( FOLD ) CEO John Crowley on Phase III Fabry Monotherapy Study Results (Transcript)

      Headlines

      Wed, 20 Aug 2014

      By SA Transcripts : Amicus Therapeutics , Inc. (NASDAQ: FOLD ) Phase III Fabry Monotherapy Study Results Conference ..... Good day, ladies and gentlemen, and welcome to the Amicus Phase 3 Fabry monotherapy results conference call. At

    2. Amicus Fabry disease drug candidate successful in Phase 3 trial

      Headlines

      Wed, 20 Aug 2014

      Share of Amicus Therapeutics (NASDAQ: FOLD ) are up 37% premarket on light volume in response to its report of positive results for its Fabry disease drug candidate, migalstat

    3. Amicus's fat accumulation drug effective in second late-stage study

      Headlines

      Wed, 20 Aug 2014

      Aug 20 (Reuters) - Amicus Therapeutics Inc said its experimental drug was as effective as enzyme replacement therapies (ERTs) after 18 months in patients with an inherited disorder that leads to the...

    4. Amicus' ( FOLD ) CEO John Crowley on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Thu, 7 Aug 2014

      Amicus Therapeutics , Inc. (NASDAQ: FOLD ) Q2 2014 Results Earnings Conference Call August 7, 2014 5 ..... Operator Good day, ladies and gentlemen. And welcome to the Amicus 2Q Results Conference Call and Webcast. At this time, all

    5. Amicus Therapeutics beats by $0.01, revenue in-line

      Headlines

      Thu, 7 Aug 2014

      Amicus Therapeutics (NASDAQ: FOLD ): Q2 EPS of -$0.22 beats by $0.01 . Revenue of $0.47M in-line. Shares +10.4% AH. Press Release Post your comment!

    6. Amicus Therapeutics ( FOLD ) Q2 2014 Results - Earnings Call Webcast

      Headlines

      Thu, 7 Aug 2014

      The following audio is from a conference call that will begin on August 07, 2014 at 17:00 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »

    7. Edelman's Perceptive Advisors Buying Amicus Therapeutics Ahead Of Phase III Data Release

      Headlines

      Wed, 23 Jul 2014

      position." Perceptive's most recent buy is Amicus Therapeutics (NASDAQ: FOLD ) . The fund bought 8,339,444 shares on May ..... million additional shares were added on the day that Amicus announced trial updates and analysis Complete

    8. BUZZ- Amicus Therapeutics : On track to report trial data

      Headlines

      Mon, 30 Jun 2014

      ** Says on track to report data from a late-stage trial of its genetic disorder drug in the third quarter of this year

    9. Amicus shares fall after Fabry drug fails late-stage study

      Headlines

      Thu, 20 Dec 2012

      (Reuters) - Amicus Therapeutics Inc lost nearly half of its market value after the company said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage...

    10. Amicus's shares tank after Fabry disease drug fails trial

      Headlines

      Wed, 19 Dec 2012

      (Reuters) - Amicus Therapeutics said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage study, sending its shares down 50 percent in extended...

    « Prev12Next »
    Content Partners